SG Americas Securities LLC Acquires 1,195 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

SG Americas Securities LLC raised its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 23.0% in the 4th quarter, HoldingsChannel reports. The firm owned 6,386 shares of the biopharmaceutical company’s stock after purchasing an additional 1,195 shares during the quarter. SG Americas Securities LLC’s holdings in Madrigal Pharmaceuticals were worth $3,719,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its holdings in shares of Madrigal Pharmaceuticals by 0.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 4,459 shares of the biopharmaceutical company’s stock worth $1,349,000 after purchasing an additional 30 shares during the last quarter. Centaurus Financial Inc. lifted its position in Madrigal Pharmaceuticals by 5.0% during the 3rd quarter. Centaurus Financial Inc. now owns 709 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 34 shares in the last quarter. Orion Porfolio Solutions LLC lifted its position in Madrigal Pharmaceuticals by 1.3% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 3,638 shares of the biopharmaceutical company’s stock worth $1,101,000 after buying an additional 47 shares in the last quarter. GAMMA Investing LLC grew its holdings in Madrigal Pharmaceuticals by 114.3% during the 3rd quarter. GAMMA Investing LLC now owns 90 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 48 shares during the last quarter. Finally, Global Retirement Partners LLC grew its holdings in Madrigal Pharmaceuticals by 221.7% during the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 51 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, CFO Mardi Dier sold 1,982 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $430.87, for a total transaction of $853,984.34. Following the completion of the sale, the chief financial officer owned 12,490 shares in the company, valued at approximately $5,381,566.30. The trade was a 13.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Carole Huntsman sold 910 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $493.78, for a total value of $449,339.80. Following the completion of the transaction, the insider directly owned 9,122 shares in the company, valued at approximately $4,504,261.16. This trade represents a 9.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 55,612 shares of company stock valued at $28,326,065 over the last three months. 21.50% of the stock is owned by insiders.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ:MDGL opened at $546.89 on Friday. The stock has a market capitalization of $12.55 billion, a P/E ratio of -42.49 and a beta of -1.00. Madrigal Pharmaceuticals, Inc. has a 1-year low of $265.00 and a 1-year high of $615.00. The company has a current ratio of 4.01, a quick ratio of 3.77 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $466.11 and a two-hundred day moving average price of $492.17.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The business had revenue of $321.08 million during the quarter, compared to the consensus estimate of $310.36 million. During the same period last year, the business posted ($2.71) EPS. The firm’s revenue for the quarter was up 210.8% compared to the same quarter last year. Equities analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on MDGL shares. TD Cowen reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Monday, January 12th. B. Riley Financial increased their price target on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Citizens Jmp raised their price target on shares of Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the company a “market outperform” rating in a report on Tuesday, January 20th. The Goldman Sachs Group restated a “buy” rating and issued a $571.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday, January 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Madrigal Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $685.31.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.